Eagle Bulk Shipping Inc. (NASDAQ:EGLE) has entered into an amended agreement with its lenders, withdrawing certain restrictions on the lenders in exercising their warrants in the company. Eagle Bulk Shipping Inc. (NASDAQ:EGLE) stock performance was -31.29% in last session and finished the day at $1.91. Traded volume was 4.39million shares in the last session and the average volume of the stock remained 435.66K shares. The beta of the stock remained 2.92. Eagle Bulk Shipping Inc. (NASDAQ:EGLE) insider ownership is 10.24%.
Anchor Hocking continued to operate with a minimal crew yesterday, days after the plant’s largest union agreed to contract concessions that employees hoped would send them back to work. The parent company, EveryWare Global Inc. (NASDAQ:EVRY), is taking steps to bring back more workers, but it would not comment about potential timetables. “The company is reviewing its startup plan,” said Erika Schoenberger, EveryWare’s associate general counsel. “Because the union voted to ratify these concessions, we have a critical piece toward meeting that goal.” Everyware Global Inc (NASDAQ:EVRY) dropped -20.35 percent to $2.74 Tuesday on volume of 1.38million shares. The intra-day range of the stock was $2.71 to $3.25. Everyware Global Inc (NASDAQ:EVRY) has a market capitalization of $60.61million.
China Cord Blood Corporation (NYSE:CO) was a big mover last session with its shares rising nearly 9% on the day. The move came on solid volume too with far more shares of changing hands than in a normal session. This continues the recent uptrend of the company as the stock has gained nearly 23% in the past one-month time frame. China Cord Blood Corporation (NYSE:CO)’s stock on July 08, 2014 reported a decrease of -19.78% to the closing price of $4.34. Its fifty two weeks range is $2.84 -$5.70. The total market capitalization recorded $317.25million. The overall volume in the last trading session was 1.38million shares. In its share capital, CO has 73.10million outstanding shares.
Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) announced the launch of a new product in China — bovine immunoglobulin G kits targeting China’s domestic pig farming communities. This product helps to prevent and treat blue ear disease, respiratory pneumonia, pseudorabies, swine fever and foot and mouth disease which are common diseases affecting pig in the farming industry. Skystar’s Chairman and CEO, Weibing Lu, commented, “Skystar is pleased to launch its new bovine IgG kits in China. Having performed market research with our customers, we anticipate that, the bovine IgG kits, represent an approximate $1.5M annual revenue opportunity for Skystar, upon full production. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) stock performance was -14.13% in last session and finished the day at $6.44. Traded volume was 121,334.00million shares in the last session and the average volume of the stock remained 35.13K shares. The beta of the stock remained 1.27. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) insider ownership is 19.10%.